首页> 外文期刊>Organic & biomolecular chemistry >Conversion of 2-deoxy-D-ribose into 2-amino-5-(2-deoxy-β-D-ribofuranosyl) pyridine, 2'-deoxypseudouridine, and other C-(2'deoxyribonucleosides)
【24h】

Conversion of 2-deoxy-D-ribose into 2-amino-5-(2-deoxy-β-D-ribofuranosyl) pyridine, 2'-deoxypseudouridine, and other C-(2'deoxyribonucleosides)

机译:2-脱氧-D-核糖转化为2-氨基-5-(2-脱氧-β-D-核呋喃核糖基)吡啶,2'-脱氧伪杜杜里定和其他C-(2'脱氧核糖核苷)

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis of 2-amino-5-(2-deoxy-β-D-ribofuranosyl) pyridine 2a, 2-amino-5-(2-deoxy-α-ribofuranosyl)-pyridine 23, 2-amino-5-(2-deoxy-β-D-ribofuranosyl)-3-methylpyridine 2b, 2-amino-5-(2-deoxy-α-ribofuranosyl)-3-methylpyridine 29 and 5-(2-deoxy-β-D-ribofuranosyl)-2, 4-dioxopyrimidine [2'-deoxypseudouridine] 30a is described. These C-nucleosides are prepared either from 2-deoxy-3, 5-O-(1, 1, 3, 3-tetraisopropyldisiloxan-2, 3-diyl)-D-ribofuranose 15 or form 2-deoxy-3, 5-O-(1, 1, 3, 3-tetraisopropyldisiloxan-1, 3-diyl)-D-ribono-1, 4-lactone 16, which are themselves prepared from 2-deoxy-D-ribose 13. The sugar derivatives are first allowed to react with the appropriate 5-lithio-pyridine or 5-lithio-pyrimidine derivatives, which are prepared from 5-bromo-2-(dibenzylamino)pyridine 12a, 5-bromo-2-[bis(4-methoxybenzyl)amino]pyridine 12b, 5-bromo-2-dibenzylamino-3-methylpyrine 25 and 5-bromo-2, 4-bis(4-methoxybenzyl)pyrimidine 33. The products from the reactions between the lithio-derivatives and the lactol 15 are cyclized under Mitsunobu conditions; the products from the reactions between the lithio-derivatives and the lactone 16 are first reduced with L-Selecride before cyclization. also under Mitsunobu conditions. In all cases, the β-anomers of the protected C-nucleosides are the predominant products. finally, the separation of the α- and β-anomers and the removal of all of the protecting groups are described.
机译:2-氨基-5-(2-脱氧-β-D-核呋喃糖基)吡啶2a,2-氨基-5-(2-脱氧-α-核呋喃糖基)-吡啶23、2-氨基-5-(2)的合成-脱氧-β-D-呋喃核糖基)-3-甲基吡啶2b,2-氨基-5-(2-脱氧-α-呋喃核糖基)-3-甲基吡啶29和5-(2-脱氧-β-D-呋喃核糖基)-参照图2,描述了4-二氧嘧啶[2′-脱氧伪神经尿苷] 30a。这些C-核苷可以由2-脱氧-3、5-O-(1、1、3、3-四异丙基二硅氧烷2,3-二基)-D-呋喃呋喃糖15制备或形成2-脱氧-3,5-本身由2-脱氧-D-核糖13制备的O-(1,1,3,3-四异丙基二硅氧烷-1,3-二基)-D-ribono-1,4-内酯16。首先是糖衍生物使其与由5-溴-2-(二苄氨基)吡啶12a,5-溴-2- [双(4-甲氧基苄基)氨基]制得的合适的5-硫代吡啶或5-硫代嘧啶衍生物反应吡啶12b,5-溴-2-二苄基氨基-3-甲基比林25和5-溴-2,4-双(4-甲氧基苄基)嘧啶33。硫代衍生物和乳醇15之间反应的产物在Mitsunobu条件;在环化之前,首先用L-硒化物还原硫代衍生物与内酯16之间反应的产物。同样在Mitsunobu条件下。在所有情况下,被保护的C-核苷的β-端基异构体都是主要产物。最后,描述了α-和β-端基异构体的分离以及所有保护基的去除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号